TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16141462
Drug: Dual RAAS
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual RAAS blockade (losartan and lisinopril)
Study: 16141462
Drug: Combined antiproteinuric
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antiproteinuric treatment
Study: 15576063
Drug: Antipanic medication
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipanic medication
Study: 9349065
Drug: Pethidine 25
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 25 mg with adrenaline 50 micrograms (adrenaline group, n = 20)
Study: 9349065
Drug: Pethidine 25
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 25 mg without adrenaline (plain group, n = 18)
Study: 9349065
Drug: Pethidine 25
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 25 mg with adrenaline 50 micrograms (adrenaline group)
Study: 9349065
Drug: Pethidine 25
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 25 mg without adrenaline (plain group)
Study: 3950827
Drug: Fluorescent green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorescent green lamps (Sylvania F20T12/G)
Study: 27392388
Drug: Steroid-eluting ethmoidal
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-eluting ethmoidal stent (SEES)
Study: 17237853
Drug: Induction 2
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction 2 cycles paclitaxel (175 mg/m2) and carboplatin (AUC 6) followed by concomitant paclitaxel (45 mg/m2) and carboplatin (AUC 2) weekly with radiotherapy (Group A)
Study: 17237853
Drug: Concomitant carboplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant carboplatin, paclitaxel (same doses as in Group A) and radiotherapy (Group B)
Study: 17237853
Drug: Only radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only radiotherapy to a total dose of 60 Gy in conventional fractionation (Group C)
Study: 14616430
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort extract (300 mg, twice daily)
Study: 14616430
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort extract (300 mg, three times daily)
Study: 14616430
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive alone (control)
Study: 10749463
Drug: Ceftriaxone for
Normalized name: Ceftriaxone for Injection
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone for 4 days (4 injections)
Study: 8932983
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human interleukin‐6 (rhIL‐6) at doses of 1, 3 or 10 micrograms/kg/day for 7 consecutive days
Study: 8932983
Drug: cyclophosphamide/G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide/G‐CSF
Study: 3931145
Drug: Alprazolam 0.5
Normalized name: alprazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.5 mg b.i.d. for 7 days
Study: 3931145
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg b.i.d. for 7 days
Study: 23432142
Drug: Omalizumab 150
Normalized name: omalizumab 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 150 mg
Study: 24039365
Drug: PPI (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI (lansoprazole 30 mg/d orally)
Study: 24039365
Drug: rebamipide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: rebamipide (300 mg orally, three times a day)
Study: 21768463
Drug: Erlotinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib plus tivantinib (ET) - erlotinib (150 mg daily) and tivantinib (360 mg twice daily)
Study: 21768463
Drug: Erlotinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib plus placebo (EP) - erlotinib (150 mg daily) and placebo
Study: 19805683
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose casopitant (150 mg PO on day 1)
Study: 19805683
Drug: 3-day oral
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day oral casopitant (150 mg PO on day 1 plus 50 mg PO on days 2 to 3)
Study: 19805683
Drug: 3-day IV/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day IV/oral casopitant (90 mg IV on day 1 plus 50 mg PO on days 2 to 3)
Study: 17078124
Drug: Recruitment for
Normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment for treatment trial
Study: 12477521
Drug: Trial culture
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial culture medium formulation
Study: 12477521
Drug: Control culture
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control culture medium formulation
Study: 9717115
Drug: Catheterization using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheterization using a hysteroscopic catheter (3-French diameter tapering to 2 French at the tip)
Study: 28983556
Drug: Ranibizumab, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab, 0.5 mg, and verteporfin photodynamic therapy (vPDT)
Study: 28983556
Drug: Ranibizumab, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab, 0.5 mg, and sham PDT
Study: 20653397
Drug: Diascorea alata
Normalized name: Dioscorea alata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diascorea alata (12 mg/sachet, 2 sachets daily for 12 months)
Study: 9154286
Drug: Latanoprost (0.35,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost (0.35, 115, and 350 micrograms/ml) administered topically to both eyes after a baseline day with vehicle (placebo).
Study: 9154286
Drug: Latanoprost (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost (10 times the clinically recommended dose for glaucoma treatment).
Study: 9154286
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) administered to asthmatic patients on baseline day.
Study: 8330470
Drug: Torsemide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide (10 mg)
Study: 26712605
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard lunch followed by normal daily activities)
Study: 23274402
Drug: Kin Keeper(SM)
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kin Keeper(SM) Cancer Prevention Intervention (treatment group)
Study: 19686327
Drug: Topical aloe
Normalized name: Alo Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aloe vera (AV)
Study: 9266098
Drug: Breast Conserving
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast Conserving Therapy (BCT)
Study: 8318241
Drug: Clonidine infusion
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine infusion
Study: 31972249
Drug: PF-06700841 30
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06700841 30 mg (n = 14)
Study: 31972249
Drug: PF-06700841 100
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06700841 100 mg (n = 7)
Study: 1623705
Drug: Conventional restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional restorative treatment
Study: 21410557
Drug: Ultraconservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraconservative treatment
Study: 19597879
Drug: Heparin responsiveness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin responsiveness in stabilized IE patients
Study: 19597879
Drug: Heparin resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin resistance
Study: 9218071
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg nocte
Study: 2979684
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (average dose 10 mg)
Study: 2979684
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam in lipid emulsion (average dose 18.4 mg)
Study: 30759357
Drug: Impairment-based manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impairment-based manual therapy
Study: 28281738
Drug: Nicorandil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (10 mg daily from 30 min before and up to 3 days after procedure)
Study: 28281738
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous hydration only)
Study: 23483064
Drug: Cefotaxime sodium
Normalized name: Cefotaxime Sodium
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime sodium 2 g/12 h and intravenous human albumin
Study: 18981044
Drug: Inhaled L-methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled L-methamphetamine (16 microg)
Study: 18981044
Drug: Inhaled L-methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled L-methamphetamine (48 microg)
Study: 12716688
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 50, 100, 200, 400, 600, or 800 micro g daily for 12 weeks
Study: 12716688
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (estimated adequate dose) 392 micro g daily
Study: 8636540
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy with transient ischemia (group I)
Study: 8636540
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy without transient ischemia (group II)
Study: 1592646
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia (IVA) with pentazocine
Study: 1972836
Drug: EMLA 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA 5% cream
Study: 30789785
Drug: Providing detailed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Providing detailed process information about conflict resolution in withholding treatment (second opinion, ethics consultation, exploring transfer to another institution)
Study: 30198057
Drug: Resminostat plus
Normalized name: resminostat
DrugBank: Resminostat (DB12392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resminostat plus sorafenib (resminostat 400 mg/day on days 1 to 5 every 14 days, sorafenib 800 mg/day for 14 days)
Study: 30198057
Drug: Sorafenib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib monotherapy (800 mg/day)
Study: 30198057
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (resminostat plus sorafenib)
Study: 30198057
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (resminostat plus sorafenib) among patients with normal-to-high baseline platelet count (≥ 150 × 103/mm3)
Study: 30198057
Drug: Sorafenib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib monotherapy among patients with normal-to-high baseline platelet count (≥ 150 × 103/mm3)
Study: 27521970
Drug: Oxycodone and
Normalized name: oxycodone and naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone and dexmedetomidine (group OD)
Study: 27521970
Drug: Oxycodone alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone alone (group O)
Study: 25561816
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and S‐1 combination therapy (recurrent group)
Study: 25561816
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and S‐1 combination therapy (unresectable group)
Study: 20215710
Drug: Intensive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid-lowering therapy with rosuvastatin (target LDL-C levels: 80 mg/dL for primary prevention, 70 mg/dL for secondary prevention)
Study: 20215710
Drug: Conventional lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional lipid-lowering therapy with pravastatin (target LDL-C level: complying with JASGL2007)
Study: 19469273
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (2 mg of estradiol and 0.5 mg of norgestrel)
Study: 15916866
Drug: L-methadone
Normalized name: dl-Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-methadone
Study: 15916866
Drug: D,L-methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: D,L-methadone
Study: 12428068
Drug: Bismuth subnitrate
Normalized name: Bismuth subnitrate
DrugBank: Bismuth subnitrate (DB13209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth subnitrate plus metronidazole and amoxicillin (group A)
Study: 12428068
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy after 3 months for group B non-responders
Study: 8880666
Drug: substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: substance abuse treatment without case management
Study: 26898340
Drug: Gentamicin impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin impregnated collagen sponge (GICS) at gentamicin dose = 6 mg/kg (n = 9)
Study: 23893101
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (PEERS intervention)
Study: 17924889
Drug: Fentanyl bolus
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl bolus administration
Study: 9024516
Drug: Heparin solution
Normalized name: heparin Injectable Solution
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin solution (25 U/ml) with vancomycin (25 mcg/ml) for daily catheter flush (HepVan)
Study: 9024516
Drug: Heparin solution
Normalized name: heparin Injectable Solution
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin solution (25 U/ml) without vancomycin (Hep)
Study: 3101502
Drug: Viscoelastic tear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscoelastic tear formulations (including hyaluronic acid and chondroitin sulfate)
Study: 3101502
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate solution
Study: 3101502
Drug: Polyvinyl alcohol
Normalized name: Polyvinyl Alcohol
DrugBank: Polyvinyl alcohol (DB11060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyvinyl alcohol or hyaluronic acid solution
Study: 31199766
Drug: Dysentery compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysentery compound (DC)
Study: 16389165
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine (5 mg/kg)
Study: 16389165
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine (7.5 mg/kg)
Study: 23178468
Drug: Somatostatin administration
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin administration
Study: 9059166
Drug: Preci-Jet 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preci-Jet 50 transjector for growth hormone delivery
Study: 9059166
Drug: Pen injection
Normalized name: Autopen Injection Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pen injection system for growth hormone delivery
Study: 8377957
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methotrexate, 15 mg weekly
Study: 2439786
Drug: Bisoprolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (20 mg)
Study: 27524403
Drug: Individual pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual pain treatment for eight weeks
Study: 24554388
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of 50‐60 min of aerobic exercise (HIGH; n = 101)
Study: 24554388
Drug: Combined dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dose of 50‐60 min of aerobic and resistance exercise (COMB; n = 104)
Study: 24554388
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of 25‐30 min of aerobic exercise (STAN; n = 96)
Study: 23301468
Drug: Acupuncture +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture + medication (electroacupuncture at Baihui, Yintang, Sishencong, Taichong, Sanyinjiao) with oral administration of madopar and fluoxetine
Study: 23301468
Drug: Medication (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (oral administration of madopar and fluoxetine)
Study: 20522567
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of lidocaine and bupivacaine
Study: 9163278
Drug: S-(+)-ketamine 1
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-(+)-ketamine 1 mg/kg
Study: 9163278
Drug: Ketamine racemate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine racemate 2 mg/kg
Study: 9163278
Drug: S-(+)-ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-(+)-ketamine 0.5 mg/kg
Study: 9163278
Drug: Ketamine racemate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine racemate 1 mg/kg
Study: 9163278
Drug: S-(+)-ketamine 2
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-(+)-ketamine 2 mg/kg
Study: 9163278
Drug: Ketamine racemate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine racemate 4 mg/kg
Study: 9163278
Drug: S-(+)-ketamine 1
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-(+)-ketamine 1 mg/kg with midazolam
Study: 9163278
Drug: Ketamine racemate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine racemate 2 mg/kg with midazolam
Study: 8369784
Drug: Fixed-triple combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-triple combination of isoniazid (750 mg), rifampicin (600 mg), and pyrazinamide (2,250 mg)
Study: 8369784
Drug: Individual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual administration of isoniazid (750 mg), rifampicin (600 mg), and pyrazinamide (2,250 mg)
Study: 31063574
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg (n=1208)
Study: 28750737
Drug: 10 ppm
Normalized name: Glycerin 1.0 g in 25 mL TOPICAL CREAM [EGF Crystal 10 ppm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ppm NO inhalation
Study: 18640991
Drug: ET-1 infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET-1 infusion (1.0-2.5 ng kg(‐1) min(‐1))
Study: 11028255
Drug: Promethazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (50 mg)
Study: 1672059
Drug: isostop group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: isostop group (isoflurane discontinued before neostigmine administration)
Study: 6839001
Drug: compressed ASA
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compressed ASA tablets (cASA)
Study: 6839001
Drug: sodium salicylate
Normalized name: Sodium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium salicylate (578 mg)
Study: 30639991
Drug: Group CBTp
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group CBTp plus treatment as usual (TAU)
Study: 30480729
Drug: Lanadelumab 150
Normalized name: Lanadelumab 150 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab 150 mg every 4 weeks (n=28)
Study: 30480729
Drug: Lanadelumab 300
Normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab 300 mg every 4 weeks (n=29)
Study: 30480729
Drug: Lanadelumab 300
Normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab 300 mg every 2 weeks (n=27)
Study: 25665812
Drug: Supplemental insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplemental insulin at bedtime for blood glucose (BG) >7.8 mmol/L
Study: 25665812
Drug: No supplemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplemental insulin except for BG >19.4 mmol/L
Study: 25665812
Drug: Supplemental insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplemental insulin at bedtime
Study: 25665812
Drug: No supplemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplemental insulin
Study: 24814472
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (mindfulness-based therapy)
Study: 19181486
Drug: antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic therapy alone (prulifloxacin 600 mg daily for 14 days)
Study: 12133539
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) at a dosage of 1.0 - 1.5 g/d